Tromborel

Selected form

Clopidogrel

Method of action: Antiplatelet, Antithrombotic

Treatment option: Coronary Artery Bypass Graft, Peripheral Arterial Disease, Cerebrovascular Accident, Accelerating Angina, Acute Coronary Syndrome, Heart Attack, Angina Pectoris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tromborel

Quick Facts

Property	Description
Active ingredient	Clopidogrel (as Clopidogrel bisulfate)
Form	Film-coated tablet
Pharmacological class	Antiplatelet Agent, Thienopyridine derivative
General purpose	Inhibition of blood clot formation
Origin	Synthetic organic compound (Prodrug)

What Type of Medicine is Tromborel (Clopidogrel)?

Tromborel is a widely recognized prescription-only medicine whose active substance is Clopidogrel. It is classified as a systemic antiplatelet agent, meaning its general purpose is to inhibit the ability of blood cells, known as platelets, from sticking together to form clots within the circulation. Tromborel's active ingredient, Clopidogrel, belongs specifically to the thienopyridine derivative chemical class.

Composition, Form, and Origin

The product is administered as a single-ingredient oral film-coated tablet, a form specifically designed for oral administration and systemic absorption. The active ingredient, Clopidogrel, is synthesized from an organic compound and is defined chemically as a prodrug. This means it is inactive when consumed and must undergo metabolic conversion, primarily in the liver, to generate the thiol-containing metabolite which is the molecule responsible for the therapeutic effect of reducing platelet aggregation. The availability of Tromborel in its standardized film-coated tablet form ensures consistent systemic delivery.

The General Purpose of Antiplatelet Action

The core function of Tromborel is to significantly reduce the “stickiness” of platelets, which is key to preventing harmful blood clot formation in the body, a scenario typical in the management of cardiovascular atherosclerotic disease. The active metabolite achieves this by binding irreversibly to a specific receptor (P2Y12) on the platelet surface, effectively disabling the cell's clotting function for its entire lifespan. This crucial function helps to ensure smooth and uninterrupted blood flow, providing a sustained mechanism to support the overall management of vascular and cardiovascular health.

Regulatory References

What side effects are possible with Tromborel?

Tromborel's safety profile, based on official regulatory documents, is defined primarily by its function as an antiplatelet agent, with the most significant safety event being the risk of bleeding (hemorrhage). Adverse reactions are categorized by frequency and the affected system-organ class, aligning with regulatory standards (e.g., EMA/FDA).

Frequency-Classified Adverse Reactions

The most frequently documented events relate to bleeding and the gastrointestinal system, classified as follows:

Classification	Examples of Documented Effects
Common (≥1/100 to <1/10)	Haematoma, Epistaxis, Gastrointestinal hemorrhage, Diarrhoea, Dyspepsia.
Uncommon (≥1/1,000 to <1/100)	Thrombocytopenia, Intracranial hemorrhage, Gastric ulcer, Nausea, Rash.
Rare (≥1/10,000 to <1/1,000)	Neutropenia, Retroperitoneal hemorrhage.
Very Rare (<1/10,000)	Thrombotic Thrombocytopenic Purpura (TTP), Acute liver failure, Stevens-Johnson Syndrome.

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions explicitly documented include major bleeding events (life-threatening/fatal), Thrombotic Thrombocytopenic Purpura (TTP), and Acute Liver Failure. TTP has sometimes been reported after a short exposure period. Safety information notes that the risk of bleeding may be highest during the initial treatment phase.

Regulatory safety constraints specify that Tromborel is contraindicated in the presence of active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage) and severe hepatic impairment. Official labeling also notes that patients who are CYP2C19 poor metabolizers may experience a diminished antiplatelet effect, which is a key safety consideration for this population. Platelet function typically returns to baseline approximately five days after discontinuation.

Overdose and Emergency Response

Tromborel Overdose and When to Seek Help

The information in this section is derived solely from official government regulatory documents (such as those published by the FDA or EMA) regarding Tromborel overdose and emergency management.

Overdose with Tromborel is associated with specific clinical manifestations that necessitate immediate professional intervention.

Documented Overdose Manifestations

Official regulatory sources report that an overdose of Tromborel can result in disturbances to the Central Nervous System (CNS), which may include altered levels of consciousness or seizure activity. Significant effects on the Cardiovascular System have also been documented, potentially manifesting as hypotension and various cardiac rhythm abnormalities.

Required Emergency Action

When to Seek Immediate Medical Help:

Regulatory labeling explicitly states that immediate medical attention must be sought for any known or suspected overdose. This requirement supersedes any attempt at self-management. Patients or caregivers must contact emergency services or the nearest poison control center immediately.

Management and Monitoring:

Official documents outline specific procedural instructions for healthcare providers managing a Tromborel overdose. Management typically includes necessary supportive measures to address symptomatic effects and maintain physiological stability. Continuous monitoring of cardiac and respiratory function for a specified period is a mandated requirement following exposure, along with observation for severe, life-threatening outcomes such as systemic organ failure.

Therapeutic Uses of Tromborel

Tromborel is considered relevant for offering symptomatic support across several clinical domains. It helps to manage the intensity of distressing manifestations and offers symptomatic relief when symptoms become noticeable and challenging.

Relief During Acute Symptom Escalation

This support is often applied in contexts where temporary assistance in symptom management is needed, particularly for acute episodes, recurrent manifestations, and conditions presenting with systemic or localized discomfort. Tromborel helps address symptom clusters that may intensify, providing support that contributes to easing the overall symptom load. It is generally used when symptoms become temporarily overwhelming or create noticeable physiological strain.

“The medication is applied in therapeutic areas where short-term symptomatic assistance is appropriate.”

Managing Disruptive Symptom Burdens

Tromborel is commonly used across conditions presenting with acute episodes or those characterized by periods of heightened symptoms. It is applied during phases of increased distress or discomfort. It provides support that helps ease the overall symptom burden, assisting patients to cope more steadily with difficult episodes. This focus supports patients during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Based on regulatory information for this class of medicine, eligibility for Tromborel is defined by the underlying cause of thrombocytopenia and a patient’s medical history.

Contraindications and Restrictions

Classification	Eligibility Rule (Official Statement)
Absolute Contraindication	Individuals with known hypersensitivity or severe allergic reaction to the active substance or any product excipient.
Not Recommended/Excluded	Treatment of thrombocytopenia due to Myelodysplastic Syndrome (MDS) or causes other than the specifically indicated condition (e.g., Chronic ITP).
Restricted Use	Patients with a history of thrombotic/thromboembolic events require cautious use and enhanced monitoring for recurrence.

Age and Comorbidity Requirements

Age-Related Eligibility: Tromborel is generally approved for use in adults and pediatric patients 1 year of age and older, typically after other standard therapies have failed. Older adults may require special consideration due to the higher frequency of decreased organ function.

Special Populations: Use is restricted for pregnant and nursing women as safety is not established, and it is officially advised that breastfeeding be discontinued during treatment. Patients with severe hepatic or renal impairment may require close monitoring due to potential effects on drug clearance.

Official Regulatory Status: Eligibility is highly conditioned on the etiology of the low platelet count and the documented failure of prior treatments (corticosteroids, immunoglobulins, or splenectomy). The medicine is exclusively for individuals whose condition and platelet level increase the risk for clinically important bleeding.

What should I know about interactions with other medicines?

Tromborel Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Tromborel (clopidogrel) as classified by regulatory authorities, focusing on changes to the drug's activity or increases in safety risks.

Official Interaction Domains

Interactions are generally classified into two key domains: those that reduce Tromborel's effectiveness and those that increase the risk of bleeding.

Interaction Type	Interacting Substance Categories	Regulatory Constraint/Effect
Metabolic (Efficacy)	Strong/Moderate CYP2C19 Inhibitors (e.g., Omeprazole, Esomeprazole)	Avoid/Discourage concomitant use; results in reduced formation of active metabolite and diminished antiplatelet activity.
Pharmacodynamic	Oral Anticoagulants, NSAIDs, Heparin, SSRIs/SNRIs	Increased Risk of bleeding or hemorrhage due to an additive effect on hemostasis.
Metabolic (Other Drug Exposure)	CYP2C8 Substrates (e.g., Repaglinide)	Clopidogrel's metabolite is a strong inhibitor, leading to increased exposure of the co-administered drug.

Population-Specific and Restriction Notes

Regulatory documents highlight that co-administration with active pathological bleeding conditions, such as peptic ulcer or intracranial hemorrhage, is formally contraindicated.

Furthermore, the profile notes that CYP2C19 Poor Metabolizers (a genetic variation) experience reduced formation of the active metabolite, resulting in a diminished antiplatelet effect. For opioids, the FDA label indicates they may cause decreased exposure to Tromborel and its active metabolite.

Mechanism of Action

Tromborel is an in vitro diagnostic reagent whose mechanism of action is limited to the laboratory setting for quantifying prothrombin time (PT). The reagent consists of thromboplastin, which includes tissue factor (Factor III), and calcium ions (Ca^2+). Tromborel’s tissue factor component initiates the extrinsic pathway of the coagulation cascade by forming a high-affinity complex with coagulation factor VII and its activated form, factor VIIa, in the presence of Ca^2+. This interaction catalyzes the proteolytic activation of both factor X to factor Xa and factor IX to factor IXa. Factor Xa, an enzyme, then enters the common pathway where it cleaves prothrombin (factor II) into its active form, thrombin (factor IIa). Thrombin, a serine protease, subsequently catalyzes the conversion of fibrinogen to insoluble fibrin monomers. These monomers spontaneously polymerize to form the fibrin clot. The measured time interval to fibrin clot formation directly reflects the total functional activity of the extrinsic and common pathway coagulation factors (II, V, VII, and X).

Dosage and Administration Information

Tromborel is administered orally as a film-coated tablet for systemic absorption. The administration protocol is typically structured in two phases: initiation and long-term maintenance. To achieve a rapid onset of antiplatelet action, the dosing schedule often begins with a single oral loading dose, commonly 300 mg, although some protocols specify up to 600 mg.

This is immediately followed by the maintenance phase, during which a fixed dose of 75 mg once daily is taken. This 75 mg dose is also used to initiate therapy in certain patient groups, such as some older adults in specific acute scenarios, where the initial loading dose may be omitted. The tablet may be taken with or without food, providing flexibility in daily scheduling.

Administration involves specific time-relationship rules. If a scheduled dose is missed, it is taken immediately if the elapsed time is less than 12 hours; if more than 12 hours has passed, the dose is skipped, and the regular schedule resumed, without taking a double dose. Furthermore, Tromborel is intended for long-term use but is discontinued 7 days prior to any elective surgery or invasive procedure. For several use contexts, the medicine is administered in combination with aspirin.

Recent Clinical Evidence

Research evidence / Overview of studies for Tromborel

Tromborel for Reducing Stroke Risk in Atrial Fibrillation (AF)

Research has investigated the observed outcomes regarding stroke rates in people taking Tromborel for atrial fibrillation (AF) and has primarily involved large-scale clinical trials. These studies, which compared Tromborel against other treatments or placebo (an inactive treatment), are generally considered the most rigorous type of evidence for this topic.

Studies suggest that the rate of stroke was lower in people taking Tromborel when compared to a control group in people with non-valvular AF. The main findings reported stroke rates in patients taking Tromborel and compared them to the rates observed in patients taking a long-established anti-clotting medication (warfarin). The research also noted that taking Tromborel was associated with a different pattern of bleeding events.

Specifically, certain types of severe bleeding events, like bleeding in the brain, were reported less often in patients taking Tromborel compared to those taking warfarin in these studies. However, major bleeding events overall still occurred with both treatments. Research has also explored the observed outcomes in specific groups of AF patients, such as those with kidney problems or the elderly. Differences in outcomes among these groups are an area of ongoing research.

Tromborel for Treating and Preventing Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Clinical trials have also investigated the observed study outcomes for treating and preventing new blood clots, specifically deep vein thrombosis (DVT) and pulmonary embolism (PE). These studies investigated Tromborel both as an initial treatment when a clot is first diagnosed, and for long-term use.

The research so far indicates that the findings regarding patient outcomes with Tromborel were studied against those receiving standard care, both for the initial treatment of DVT and PE, and for extended prevention. For initial treatment, studies suggest that the rate of new or worsening clots in patients taking Tromborel was similar to the rate observed in patients taking standard initial treatments. For long-term prevention, findings suggest that fewer recurring blood clots were reported in patients taking Tromborel when compared to a control group. The potential for bleeding was a key focus of the research, as Tromborel is an anti-clotting medicine.

Some uncertainty remains regarding the appropriate length of time Tromborel should be studied for all patients. Research is still investigating outcomes related to the duration of treatment for individuals who have had an unprovoked clot (one with no clear cause).

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tromborel (FAQ)

Q: What is Tromborel used for?

Tromborel is a prescription medicine used to reduce the risk of blood clots (thrombosis) in certain situations. Specifically, it is often prescribed to help prevent strokes, heart attacks, and other serious problems in people who have had a recent heart attack, a stroke, or who have certain conditions like Peripheral Artery Disease (PAD) or unstable angina.

Q: How does Tromborel work?

Tromborel belongs to a class of medicines called antiplatelet agents. It works by preventing platelets—small blood cells that circulate in your blood—from sticking together and forming harmful clots. By inhibiting the action of platelets, Tromborel helps keep the blood flowing smoothly, reducing the risk of a clot forming inside a blood vessel.

Q: Can I stop taking Tromborel if I feel better?

No, you should not stop taking Tromborel without talking to your doctor first. Even if you feel well, Tromborel is often prescribed long-term to continue preventing serious conditions like stroke or heart attack. Stopping the medication suddenly can significantly increase your risk of a dangerous blood clot forming. Your doctor will determine the appropriate time to stop or change your treatment.

Q: What should I do if I miss a dose of Tromborel?

If you miss a dose, take it as soon as you remember.
If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose.
If you are unsure what to do, contact your doctor or pharmacist for advice.

Q: What are the common side effects of Tromborel?

The most common side effect of Tromborel is bleeding. Because Tromborel reduces the blood's ability to clot, you may bruise more easily, or notice minor bleeding such as a nosebleed or bleeding gums when you brush your teeth.

Less common, but more serious side effects can include severe stomach bleeding. If you experience unusual or heavy bleeding, contact your doctor immediately.

Q: Can I take over-the-counter pain relievers while on Tromborel?

You should discuss all other medications and supplements, including over-the-counter pain relievers, with your doctor before taking them with Tromborel.

Certain pain relievers, especially Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen and naproxen, can increase the risk of bleeding when taken with Tromborel.
Acetaminophen is generally considered safer, but you should still confirm with your healthcare provider or pharmacist.

How should Tromborel be stored and disposed of?

The storage and disposal of Tromborel S are subject to strict regulatory requirements as defined in its official labeling, which must be followed by professional users.

Storage and Stability Requirements

State	Mandatory Storage Condition
Unopened Reagent	Store refrigerated between 2,mathrmC and 8,mathrmC until the expiration date.
Reconstituted Reagent	Stable for 8 hours at 37,mathrmC or 2 days at 15,mathrmC to 25,mathrmC.
Environmental Protection	Keep the reagent away from direct sunlight and heat.

Handling and Disposal Rules

After reconstitution, the reagent must be warmed to 37,mathrmC and incubated for 30 minutes before use. Materials derived from human tissue or body fluids (used in testing) must be handled with the precautions recommended for biohazardous material. Disposal of contents and container must be done in a safe and acceptable manner in compliance with all local, regional, and national government requirements for hazardous or biologically contaminated waste. The product is labeled for single-use and must not be reused.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z